Quotient Clinical and Bend Research Announce Collaboration To Accelerate Advancement of New Medicines
Bend Research Inc. and Quotient Clinical, a business unit of Quotient Bioresearch, announced a nonexclusive collaboration that can speed the advance of compounds to clinical trials and expand options for drug delivery.
The collaboration combines Bend Research’s advanced drug formulation capabilities and Quotient’s clinical trial design service, RapidFACTTM. The result is a clinical trial program that will allow clients to screen and select optimized formulations rapidly during human testing. For example, optimum bioavailability-enhancing formulations relying on amorphous and nanocrystalline dispersions can be quickly identified using the highly flexible clinical trial designs pioneered by Quotient.
“This collaboration takes advantage of the proven strengths of our two companies,” said Bend Research President and CEO Rod Ray. “The versatility of designing and implementing clinical trials using RapidFACT provides our clients with a game-changing advantage in advancing their compounds.”
Mark Egerton, Managing Director of Quotient Clinical, agreed on the value of the collaboration. “Poorly soluble compounds are becoming ever more prevalent in the industry’s pipeline, and we have many customers who require formulation help to advance such problematic compounds. Access to Bend Research’s leading formulation expertise through this collaboration will provide our customers with reliable, rapid and efficient drug formulation platforms,” he said.
Accessing Bend Research formulations at Quotient’s clinical research site means that clinical studies can happen much more quickly than was previously possible. One client has already taken advantage of the collaboration with the successful transfer of a Bend Research formulation to Quotient’s cGMP manufacturing facility in Nottingham, U.K.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Excess weight, obesity more deadly than previously believed - One in six U.S. adult deaths are related to country's 'obesogenic' environment, study suggests
New technology could aid stem cell transplantation research
Taking aim at skin bacteria - Enzyme treatment of skin samples improves microbiome analysis
Autifony Therapeutics announces initiation of Phase IIa study for first-in-class drug to treat tinnitus
SeaBeLife awarded over €1.5 million in i-Nov innovation competition - Funding for company’s SeaBeEYE project will be used to develop new therapeutic approach for geographic atrophy – advanced form of dry AMD
Ion channel VRAC enhances immune response against viruses - New strategies against DNA viruses and cancer
Tracking down minorities in kitchen sponges - First study on non-bacterial microbiota in used kitchen sponges
Selvita Signs a Drug Discovery Services Contract With Rottapharm Madaus
How chemicals in plastic may cause lower IQ levels - The effects of environmental chemicals at the molecular level
Novel gene drives development of different types of ovarian cancer
